Dr. Dittrich brings more than 20 years of cardiac therapeutic research and clinical development experience to support Leading BioSciences’ expanding clinical pipeline. Prior to joining Leading BioSciences, Dr. Dittrich served as chief medical officer of Laguna Pharmaceuticals, which was developing a drug to treat atrial fibrillation. Previously, he held executive leadership positions at Sorbent Therapeutics, NovaCardia (acquired by Merck & Co.) and Sequel Pharmaceuticals, which he co-founded and spun out from NovaCardia following the Merck acquisition. Earlier in his career, Dr. Dittrich oversaw clinical development and regulatory affairs at Molecular Biosystems Inc. and Alliance Pharmaceutical Corp., and was instrumental in gaining U.S. Food and Drug Administration approval of two cardiovascular imaging agents. He also served on the full-time faculty of University of California, San Diego Department of Medicine and earlier, as a clinical professor of medicine at UCSD. Dr. Dittrich is currently a director for Mast Therapeutics. He holds a Bachelor of Science from the University of Iowa and an M.D. from the University of Iowa Carver College of Medicine, where he serves as adjunct professor of medicine and chair of the François M. Abboud Cardiovascular Research Center. He completed his residency in internal medicine and clinical fellowship in cardiology at UCSD.